07:00 , Sep 25, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Activin A receptor type 1C (ACVR1C; ALK7) Mouse studies suggest inhibiting ALK7 in adipose tissue...
07:00 , Sep 25, 2014 |  BC Innovations  |  Targets & Mechanisms

ALK7's obese functions

Reduced b-adrenergic signaling has long been associated with obesity, but the likelihood of triggering cardiovascular side effects has prevented companies from targeting the pathway for weight control. Now, a new-and possibly safer-way to upregulate b-adrenergic...
07:00 , May 29, 2008 |  BC Innovations  |  Targets & Mechanisms

Moving Upstream of Diabetes

There is a growing consensus in the medical community that early intervention is essential for treating diabetes.1 However, there are no approved treatments for metabolic syndrome, a complex set of conditions that often precedes diabetes....
07:00 , May 29, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease ...